SLAS Technology’s new volume spotlights how today’s life-science research is tightening the feedback loop between experimentation, automation, and evidence. Published on May 29, 2026, the issue reflects a field moving rapidly from proof-of-concept toward repeatable, measurable workflows—whether in genomics, imaging, assay development, or high-throughput screening.
At the core is a review on viral vector gene therapy, laying out fundamental principles and comparing alternative evaluation models. It emphasizes how vector performance is not only determined by efficacy, but also by stability and safety—two practical constraints that shape how therapies translate into clinical settings.
Technical briefs extend this theme into tools and infrastructure. OT2Eye, for example, introduces image-based detection of labware conditions for the Opentrons OT-2 platform, turning visual states into machine-readable status that can be integrated into AI-driven automation. Other briefs tackle bottlenecks such as solvent evaporation efficiency and quantification consistency in colorimetric assays, highlighting how engineered peripherals can accelerate routine lab steps while preserving data quality.
Original research spans diagnostic imaging and translational workflows. Diffusion tensor imaging paired with tractography in children with autism reveals microstructural differences in major white-matter pathways compared with controls, illustrating how advanced imaging analytics can sharpen biological interpretation. In lab automation, a proposed evaluation method for automated solid dosing targets mid-scale tasks, addressing risk reduction and operational efficiency in daily biotech pipelines.
Robotics and computation also make a strong appearance. A GPT-enhanced automation platform uses natural-language instructions to coordinate multi-brand robots, aiming to reduce programming barriers while enabling complex experimental sequences. In parallel, a humanoid robotic system for iPSC culture and organoid generation (“Maholo LabDroid”) targets long-term reliability by coupling real-time imaging with flexible liquid handling to improve predictive power.
The issue further underscores the importance of experimental rigor. A SARS-CoV-2 nsp3 protease HTS campaign identifies metal contamination as a driver of false positives, illustrating why counter-screens can prevent wasted resources during drug discovery. Elsewhere, a microfluidic fluid-removal system (“Stacks Insert System”) improves throughput and uniformity in low-volume exchanges—an engineering advance designed for reproducibility.
Overall, Volume 38 pairs biological discovery with practical, scalable technologies, reinforcing SLAS Technology’s focus on translating innovation into dependable laboratory practice. For readers and practitioners, the collection signals where the next gains in speed, accuracy, and accountability are likely to emerge.
Subject of Research: Life sciences and laboratory automation (viral gene therapy, imaging analytics, liquid-handling automation, microfluidics, high-throughput screening, machine learning)
Article Title: SLAS Technology, Vol. 38 (Volume 38 of SLAS Technology)
News Publication Date: 29-May-2026
Web References: (Not provided in the provided content)
References: (Not provided in the provided content)
Image Credits: SLAS Publishing
Keywords
Life sciences; biotechnology; high throughput screening; drug discovery; machine learning; artificial intelligence; laboratory automation; robotics; microfluidics; viral vectors
